IRLAB Therapeutics AB (publ)

Research IRLAB Therapeutics AB (publ) (IRLAB-A) on Bullrun: market cap SEK 105.72M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerIRLAB-A
• ExchangeST
• CountrySweden
• SectorHealthcare
• IndustryBiotechnology
• CurrencySEK
• Market capSEK 105.72M
• Financial periodFY2024
• RevenueSEK 94.63M
• Revenue growth1566.6%
• Net income-SEK 83.13M
• Free cash flow-SEK 65.79M

Valuation Snapshot

latest market cap is SEK 105.72M.

About IRLAB Therapeutics AB (publ)

IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis;

Frequently asked questions

What is IRLAB Therapeutics AB (publ)'s market cap?

IRLAB Therapeutics AB (publ)'s market capitalization is SEK 105.72M.

What does IRLAB Therapeutics AB (publ) do?

IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States.